Skin Anarchy

Send us Fan Mail
In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Morgan Gordon, VP of Brand Development and Marketing at Salon Perfect and creator of Sliick, for a candid look at what it really takes to build—and sustain—a modern beauty brand. From her early days as a licensed cosmetologist to leading innovation at scale, Morgan brings a rare perspective that bridges professional beauty and retail execution. 
What emerges quickly is a shift in how beauty brands operate today. The industry no longer moves in predictable cycles—brands are now responding to consumers in real time. Trends evolve within weeks, not seasons, and relevance depends on how closely brands stay connected to what consumers are actually saying, searching, and using. For Morgan, success comes down to translation: turning fast-moving signals into products that meet real needs, without losing quality or execution. 
The conversation also pulls back the curtain on retail realities. Getting into major retailers is only the beginning—staying there requires constant innovation, operational precision, and the ability to deliver at scale. This becomes even more critical as at-home beauty continues to reshape consumer behavior, creating demand for products that replicate professional results with simplicity and ease.
That insight led to the creation of Sliick, a brand built to reimagine at-home waxing by removing friction from the entire experience. Instead of intimidating systems, Sliick focuses on intuitive design, streamlined formulas, and a more approachable user experience.
Ultimately, this episode reveals that modern beauty success isn’t about predicting trends—it’s about evolving with the consumer in real time.
Listen to the full episode to hear Morgan Gordon break down the mechanics of scaling a beauty brand and staying relevant in today’s fast-moving industry.
Shop Sliick & Salon Perfect
Don’t forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.
Reach out to us through email with any questions.
Sign up for our newsletter!
Shop all our episodes and products mentioned through our ShopMy Shelf!
Support the show

Send us Fan Mail
In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Tom Terranova to explore a side of aesthetic medicine that patients rarely see—but that ultimately determines their safety: infrastructure. While most conversations focus on results, pricing, or provider reputation, this episode shifts the lens to what happens behind the scenes, where clinical protocols, operational systems, and regulatory gaps quietly shape outcomes.
Terranova shares the mission behind QUAD A, a nonprofit that has long established safety standards in surgical settings and is now expanding into the rapidly growing med spa space. As aesthetic treatments move further into consumer-driven environments, the industry faces a critical challenge: demand has scaled faster than standardization.
One of the most compelling insights from the conversation is the idea that risk in aesthetics is not binary—it’s stratified. Procedures often perceived as “low risk” can vary significantly in complexity and potential for harm. Yet unlike traditional medicine, med spas have lacked a clear framework to define and manage that risk. QUAD A’s tiered approach introduces a more structured way to evaluate procedures, shifting how both providers and patients should think about safety.
The discussion also challenges a common assumption: that credentials alone ensure safe care. Terranova emphasizes that true safety depends on more than technical skill—it requires the ability to recognize complications, respond in real time, and operate within a system designed for consistency and accountability. Ultimately, this episode reframes safety as something systemic, not superficial.
Listen to the full episode to hear Tom Terranova break down the hidden gaps in aesthetic medicine and what every patient should understand before choosing where to get treated.
Learn more about QUAD A
Don’t forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.
Reach out to us through email with any questions.
Sign up for our newsletter!
Shop all our episodes and products mentioned through our ShopMy Shelf!
Support the show

Send a text
In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Stephanie Culler, co-founder and CEO of Persephone Biosciences, to explore one of the most rapidly evolving frontiers in modern health science: the human microbiome. From early immune development to cancer therapy, the conversation reveals how the trillions of microbes living in our bodies may shape health in ways scientists are only beginning to understand.
Dr. Culler’s path into microbiome research began with a personal mission to understand disease after losing both of her grandmothers to cancer. Following her PhD at the California Institute of Technology, where she studied gene therapy approaches to cancer, she moved into industrial biotechnology and microbial engineering. That work eventually led her to co-found Persephone Biosciences, a company focused on translating microbiome science into real-world therapeutics and consumer health solutions.
A major focus of the discussion centers on the infant microbiome and its role in shaping immune development. Dr. Culler explains how microbes transferred during birth and nourished through breast milk help “train” the immune system in the earliest stages of life. Yet modern research suggests that key beneficial bacteria—particularly Bifidobacterium infantis—have dramatically declined in Western infants. In large-scale studies conducted by Persephone, only a small percentage of U.S. infants carry adequate levels of this once-dominant microbe.
The conversation also explores how microbiome balance may influence responses to cutting-edge cancer treatments like immunotherapy. Emerging research suggests that gut bacteria can significantly affect how patients respond to checkpoint inhibitors, opening the door to microbiome-based interventions that could enhance treatment outcomes.
Listen to the full episode to hear Dr. Stephanie Culler explain how microbiome science is transforming our understanding of immunity, disease prevention, and the future of medicine.
Learn more about Persephone Biosciences
Don’t forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.
Reach out to us through email with any questions.
Sign up for our newsletter!
Shop all our episodes and products mentioned through our ShopMy Shelf!
Support the show

Send a text
In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Elana Drell Szyfer, president of Cosmetic Executive Women (CEW) and one of the most influential leaders in the global beauty industry. With more than three decades of experience spanning companies like Chanel, L’Oréal, Avon, Estée Lauder, and RéVive, Elana offers a rare behind-the-scenes look at how careers in beauty evolve—and what it takes to navigate an industry that constantly reinvents itself.
Elana's path into beauty was anything but conventional. Originally a history major who imagined a future in nonprofit arts philanthropy, her first role at the Juilliard School focused on connecting donors with scholarship recipients. A shift toward business studies eventually led her into the beauty world through a position at Chanel’s family office. Determined to move closer to the operating side of the industry, she studied trade publications, reached out to industry leaders directly, and ultimately landed at L’Oréal—where her career in beauty truly began.
Over the next two decades, Elana built a foundation in marketing leadership across some of the industry’s largest brands. Later, she transitioned into the entrepreneurial side of beauty, leading privately backed companies and guiding brands through transformation, acquisition, and growth—including her tenure as CEO of RéVive. Along the way, she witnessed firsthand how dramatically the beauty landscape has evolved, from traditional advertising and retail counters to today’s fragmented world of social media, influencer discovery, and science-driven storytelling.
As she steps into her new role at CEW, Elana reflects on leadership, the future of marketing, and the growing need for clarity around industry buzzwords like biotech and longevity.
Listen to the full episode to hear Elana Drell Szyfer share lessons from her career and her vision for the future of the beauty industry.
Learn more about CEW
Don’t forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.
Reach out to us through email with any questions.
Sign up for our newsletter!
Shop all our episodes and products mentioned through our ShopMy Shelf!
Support the show

Send us Fan Mail
In this special episode of Skin Anarchy, Dr. Ekta Yadav welcomes back Madhavi Gavini, founder of Droplette—one of the earliest science-forward brands featured on the show. What once felt like a radically different approach to skincare technology now feels increasingly relevant as the industry shifts toward biologics, regenerative ingredients, and delivery science. The conversation revisits Droplette’s origins and explores why effective delivery may be the missing piece in modern skincare innovation.
Gavini’s journey into skincare began far outside the beauty industry. With a background in pharmaceutical development, she spent years designing therapies for pediatric diseases, where she encountered one of medicine’s most persistent challenges: delivery. Even when researchers identify the therapeutic molecule that could help treat a condition, getting that molecule into the correct layer of skin is often the hardest part. That realization became the foundation of Droplette’s technology, originally developed alongside MIT-affiliated researchers to enable large molecules to reach skin tissue without needles or barrier injury.
The Droplette device generates high-velocity, submicron droplets capable of moving ingredients past the stratum corneum—the skin’s protective outer barrier—allowing molecules far larger than traditional topical ingredients to access viable layers of skin. The implications extend beyond cosmetics, with ongoing collaborations exploring delivery for antibiotics, gene therapies, and other advanced biologics.
The episode also dives into the science behind exosomes—one of the most talked-about yet misunderstood areas in regenerative skincare. Gavini explains what exosomes are, why sourcing and stability matter, and why many topical exosome products degrade or fail to penetrate the skin barrier. Double Board-Certified Dermatologist, Dr. Dan Belkin, also shares his clinical perspective on how exosomes are currently used in dermatology and why reliable sourcing, cold-chain handling, and effective delivery systems are essential for maintaining biological activity.
Listen to the full episode to hear Madhavi Gavini explain how Droplette is bringing pharmaceutical-grade delivery science into the future of regenerative skincare.
Use discount code 'ANARCHY' to get the Exosome Starter Set on subscription for just $349
SHOP DROPLETTE
1.Quek BL, Srinivas RL, Gavini MP. Droplette: a platform technology to directly deliver nucleic acid therapeutics and other molecules into cells and deep into tissue without transfection reagents. Methods Mol Biol. 2022;2398:211-230. doi:10.1007/978-1-0716-1811-0_14.

2.Mahmood A, et al. Droplette—a fluid dynamics-driven platform for transdermal and intracellular delivery of large molecules. FASEB J. 2018;31(S1):924.7.

3.Pulakat L, Chen HH, Gavini MP, Ling LA, Tang Y, Mehm A, et al. Transdermal delivery of high molecular weight antibiotics to deep tissue infections via Droplette Micromist Technology Device (DMTD). Pharmaceutics. 2022;14(6):1134
*This is a sponsored collaboration
Support the show